Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Randomized, Parallel-Group, Phase III Study of the Efficacy and Safety of Hercules Plus Taxane Versus Herceptin Plus Taxane as First Line Therapy in Patients With HER2-Positive Metastatic Breast Cancer

Trial Profile

A Multicenter, Double-Blind, Randomized, Parallel-Group, Phase III Study of the Efficacy and Safety of Hercules Plus Taxane Versus Herceptin Plus Taxane as First Line Therapy in Patients With HER2-Positive Metastatic Breast Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab (Primary) ; Docetaxel; Paclitaxel
  • Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms HERITAGE
  • Sponsors Mylan
  • Most Recent Events

    • 01 Jul 2021 In this analysis, efficacy endpoints were reported in all patients who enrolled after the second protocol amendment (intention-to-treat population [ITT]), which excluded patients who had already received first-line therapy.
    • 01 Jul 2021 Results reporting final overall survival (OS) from HERITAGE published in the Breast Cancer Research and Treatment
    • 02 Dec 2019 According to Mylan N.V media release, Dr. Hope S. Rugo, professor of medicine at the University of California, San Francisco, is lead author of the HERITAGE study
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top